

Haemonetics stock hits a new 52-week high after CSL Plasma outlines a sweeping rollout of its technology across existing U.S. centers.
You can purchase shares of Haemonetics (NYSE:HAE) through any online brokerage.
Other companies in Haemonetics’s space includes: Alcon Inc (NYSE:ALC), Medline Inc (NASDAQ:MDLN), Solventum Corp (NYSE:SOLV), The Cooper Companies Inc (NASDAQ:COO) and Align Technology Inc (NASDAQ:ALGN).
Haemonetics has a consensus price target of $112.09.
The stock price for Haemonetics (NYSE: HAE) is $119.4 last updated October 29, 2026 at 10:24 AM EDT.
There are no upcoming dividends for Haemonetics.
Haemonetics does not have any upcoming earnings scheduled.
There is no upcoming split for Haemonetics.
Haemonetics is in the Health Care sector and Health Care Equipment & Supplies industry. They are listed on the NYSE.
Haemonetics Corp aims to improve patient care and reduce the cost of healthcare by providing medical products and solutions in the blood and plasma component collection, surgical suite, and hospital transfusion service spaces. As such, the company...